The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population
Open Access
- 1 August 2008
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (8) , 2253-2257
- https://doi.org/10.2337/db07-1807
Abstract
OBJECTIVE— Hepatic glucokinase (GCK) is a key regulator of glucose storage and disposal in the liver, where its activity is competitively modulated, with respect to glucose, by binding to glucokinase regulatory protein (GCKR) in the presence of fructose 6-phosphate. Genome-wide association studies for type 2 diabetes identified GCKR as a potential locus for modulating triglyceride levels. We evaluated, in a general French population, the contribution of the GCKR rs1260326-P446L polymorphism to quantitative metabolic parameters and to dyslipidemia and hyperglycemia risk. RESEARCH DESIGN AND METHODS— Genotype effects of rs1260326 were studied in 4,833 participants from the prospective DESIR (Data from an Epidemiological Study on the Insulin Resistance syndrome) cohort both at inclusion and using the measurements at follow-up. RESULTS— The minor T-allele of rs1260326 was strongly associated with lower fasting glucose (−1.43% per T-allele; P = 8 × 10−13) and fasting insulin levels (−4.23%; P = 3 × 10−7), lower homeostasis model assessment of insulin resistance index (−5.69%; P = 1 × 10−8), and, conversely, higher triglyceride levels (3.41%; P = 1 × 10−4) during the 9-year study. These effects relate to a lower risk of hyperglycemia (odds ratio [OR] 0.79 [95% CI 0.70–0.88]; P = 4 × 10−5) and of incident cases during the study (hazard ratio [HR] 0.83 [0.74–0.95]; P = 0.005). Moreover, an additive effect of GCKR rs1260326(T) and GCK (−30G) alleles conferred lower fasting glycemia (P = 1 × 10−13), insulinemia (P = 5 × 10−6), and hyperglycemia risk (P = 1 × 10−6). CONCLUSIONS—GCKR-L446 carriers are protected against type 2 diabetes despite higher triglyceride levels and risk of dyslipidemia, which suggests a potential molecular mechanism by which these two components of the metabolic syndrome can be dissociated.Keywords
This publication has 19 references indexed in Scilit:
- Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective StudyDiabetes, 2008
- G(−30)A Polymorphism in the Pancreatic Promoter of the Glucokinase Gene Associated With Angiographic Coronary Artery Disease and Type 2 Diabetes MellitusCirculation, 2004
- Differences in regulatory properties between human and rat glucokinase regulatory proteinBiochemical Journal, 2004
- Mutations in the glucokinase regulatory protein gene in 2p23 in obese French caucasiansDiabetologia, 2003
- Association of Fasting Plasma Glucose With Heart Rate Recovery in Healthy AdultsDiabetes, 2002
- Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase ExpressionDiabetes, 2001
- Treatment of Type 2 Diabetes by Adenoviral-Mediated Overexpression of the Glucokinase Regulatory ProteinDiabetes, 2001
- The Role of the Regulatory Protein of Glucokinase in the Glucose Sensory Mechanism of the HepatocyteJournal of Biological Chemistry, 2000
- Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulationProceedings of the National Academy of Sciences, 1999
- Short‐term control of glucokinase activity: role of a regulatory proteinThe FASEB Journal, 1994